Company intelligence / Profile preview

IVEX

Lexington, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

iVexSol offers proprietary, next-generation stable lentiviral vector production technologies, providing scalable, plasmid-free solutions enabling efficient supply of vectors for cell and gene therapies; clinical results are not applicable as iVexSol is a vector technology platform provider, not a therapeutic developer[1][4].

Modalities: Lentiviral vectorGene therapy
Industry: Non-Drug Biotech

Beyond the preview

Go deeper on IVEX.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IVEX.

Explore the full profile